Home Antibody All anti-ZFYVE26 antibodies
Also for ZFYVE26 (NM_015346)
|SPG15 antibody was raised against a 16 amino acid peptide near the carboxy terminus of human SPG15.|
|Human, Mouse, Rat
||WB: 0.5 - 1 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens zinc finger, FYVE domain containing 26 (ZFYVE26)|
|Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. SPG15 is the second gene known to be responsible for ARHSP-TCC in the Italian population. Mutations in this gene are associated with autosomal recessive spastic paraplegia-15. SPG15 encodes a protein containing a FYVE zinc finger binding domain which is thought to target these proteins to membrane lipids through interaction with phospholipids in the membrane. SPG15 mRNA is widely distributed in human tissues, as well as in rat embryos, suggesting a possible role for this protein during embryonic development. SPG15 co-localizes partially with endoplasmic reticulum and endosome markers, suggesting a role in intracellular trafficking. Multiple isoforms of SPG15 are known to exist.|
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of SPG15 in rat heart tissue lysate with SPG15 antibody at (A) 0.5 and (B) 1 µg/ml.